The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Cellectis suffers worst day in two years after Pfizer event disappoints investors

Cellectis suffered its worst day in two years on the Paris stock exchange on Monday. The 13% slump began when it became clear that a conference call held by Cellectis, Pfizer and Servier would do little more than clarify the roles of each party in their recently struck CAR-T collaboration.

With Paris spotlight on climate change, here's how Big Pharma stacks up

While pharma may not have the carbon footprint of energy or heavy manufacturing, it has other connections to environment and climate issues. The way climate change will affect public health, for instance, is a growing topic in global "green" pharma discussions, as is prescription drug pollution in the environment.

Pfizer bets up to $1B on BioAtla's approach to immuno-oncology

San Diego biotech BioAtla is sharing its immuno-oncology assets with Pfizer in a deal worth up to $1 billion, mixing and matching technologies in hopes of hitting on a winning combination.

BioAtla scores potential $1B deal with Pfizer in immuno-oncology

San Diego-based BioAtla has snagged a potential mega deal with Pfizer that seeks to combine conditionally active biologic (CAB) antibodies with proprietary antibody drug conjugate payloads as part of a deal worth a possible $1 billion to BioAtla.

Clinton keeps heat on drug industry with tax proposal for inversion deals

Hillary Clinton is putting more heat on the pharma industry, laying out a new proposal to curb corporate tax inversions weeks after Pfizer announced that it would merge with Allergan to reap the benefits of a lower tax rate.

If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says

As Pfizer moves forward with its agreed-upon $160 billion merger with Allergan, analysts expect it to eventually part ways with its consumer health business. And when it does, it's got a potential buyer in Reckitt Benckiser.

Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs

Pfizer, whose 2011 sale of a huge R&D site in the U.K. has hardly been forgotten there, is planning to shut down another research center in the country, a move that will cost about 120 jobs.

Can Pfizer finally orchestrate a winning megamerger after so many disappointments?

Pfizer's decision to buy Allergan wasn't much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read's desired tax inversion.

Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII

Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be "highly immunogenic" while also offering a good safety and tolerability profile.

'New Pfizer' heads for top of ad-spend leaderboard--and not just in pharma

Now that would be some ad budget. Pfizer is already the biggest-budget pharma advertiser by far, but if the merger with Allergan clears its hurdles, a combined "Pfizergan" could become one of the biggest advertisers, period.